Product Information
NAMZARIC 21 MG-10 MG CAPSULE is a brand product labeled by Allergan, Inc., priced at $19.9575 per EA under NDC 00456122130. Its NADAC has been published 498 times since Mar 22, 2017.
FDA first approved this application on Dec 23, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10; 21 mg/1; mg/1
Manufacturer
Allergan, Inc.NDC
00456122130
Classification
Brand
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA206439FDA Approved
12/23/2014
TE Code
AB
On Market Since
7/18/2016
Pharmacological Classes
Price Statistics
The NADAC for NAMZARIC 21 MG-10 MG CAPSULE has been published 498 times since Mar 22, 2017, and over the history we have for it it has risen 61.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $19.9575 per EA |
|---|---|
| All-time high | $19.9575 (Sep 30, 2026) |
| All-time low | $12.3324 (Mar 22, 2017) |
| 52-week high | $19.9575 |
| 52-week low | $19.7649 |
| Median price | $16.3258 |
| Average price | $16.6186 |
| Largest weekly change | +9.5% (Jan 10, 2018) |
| Weeks tracked | 498 |
| Tracking since | Mar 22, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the memantine hydrochloride and donepezil hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Allergan, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
memantine hydrochloride and donepezil hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinesterase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NAMZARIC 21 MG-10 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for NAMZARIC 21 MG-10 MG CAPSULE, manufactured by Allergan, Inc., is $19.9575 per EA (NDC 00456122130), effective Sep 30, 2026.
How has the price of NAMZARIC 21 MG-10 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for NAMZARIC 21 MG-10 MG CAPSULE has risen 61.8%. It has been tracked across 498 weekly CMS publications since Mar 22, 2017.
What are the highest and lowest recorded NADAC prices for NAMZARIC 21 MG-10 MG CAPSULE?
Since Mar 22, 2017, the NADAC for NAMZARIC 21 MG-10 MG CAPSULE has ranged from a low of $12.3324 (Mar 22, 2017) to a high of $19.9575 (Sep 30, 2026), with a median of $16.3258 per EA.
Are there cheaper alternatives to NAMZARIC 21 MG-10 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of NAMZARIC 21 MG-10 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures NAMZARIC 21 MG-10 MG CAPSULE?
NAMZARIC 21 MG-10 MG CAPSULE (NDC 00456122130) is labeled by Allergan, Inc., and CMS classifies it as a brand product.